Use of insulin and IGF-1

• US 5,756,463 A
• Filed: 12/18/1996
• Issued: 05/26/1998
• Est. Priority Date: 07/01/1994
• Status: Expired due to Fees

• Current Assignee: Chiron Corporation (Bayer AG)
• Original Assignee: Pharmacia & Upjohn AB (Pharmacia Corp.)
• Inventors: Skottner, Anna, Malmlof, Kjell, Arrhenius-Nyberg, Vibeke
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): Touzeau, P. Lynn
• Application Number:
  US08/750,735
• Time in Patent Office: 524 Days
• Field of Search: 514/12, 514/21, 514/4, 514/3, 530/303, 530/306
• US Class Current: 514/8.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: H04L 41/00 Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks

Abstract

A method is disclosed for counteracting a decrease in nitrogen balance and counteracting a decrease in protein synthesis in an individual, comprising administering to the individual a combination of insulin and IGF-I.

Claims

1. Method for counteracting a decrease in nitrogen balance and counteracting a decrease in protein synthesis in an individual, comprising administering to the individual a combination of insulin and IGF-I.

2. Method according to claim 1 for treatment of protein catabolism due to glucocortoid excess in an individual, comprising administering to the individual a combination of insulin and IGF-I.

3. Method according to claim 1 wherein the combination is administered to an individual with cardiac disease.

4. Method according to claim 1, wherein the combination contains IGF-I and insulin in a ratio of 30:

1 to 2;

1, based on molecular weight.

5. Method according to claim 4, wherein the combination contains IFG-I and insulin in a ratio of less than 10:

1, based on molecular weight.

6. Method according to claim 5, wherein the combination contains IGF-I and insulin in a ratio of less than 8:

1, based on molecular weight.

7. Method according to claim 1, wherein IGF-I is administered in a dose of 20 to 500 microgram/kg and insulin is administered in a dose of 10 to 100 microgram/kg.

8. Method according to claim 1, wherein the combination is administered to an individual having high serum level of IGFBP1.

9. Method according to claim 1, wherein the combination is administered to an individual having high serum level of low molecular weight BP.

10. Method according to claim 1, wherein the combination is administered to an individual which is insulin-resistant or which has liver disease.

11. Method according to claim 2, wherein the combination is administered to an individual with cardiac disease.

12. Method according to claim 2, wherein the combination contains IGF-I and insulin in a ratio of 30:

1 to 2;

1, based on molecular weight.

13. Method according to claim 12, wherein the combination contains IGF-I and insulin in a ratio of less than 10:

1, based on molecular weight.

14. Method according to claim 13, wherein the combination contains IGF-I and insulin in a ratio of less than 8:

1, based on molecular weight.

15. Method according to claim 2, wherein IGF-I is administered in a dose of 20 to 500 microgram/kg and insulin is administered in a dose of 10 to 100 microgram/kg.

16. Method according to claim 2, wherein the combination is administered to an individual having high serum level of IGFBP1.

17. Method according to claim 2, wherein the combination is administered to an individual having high serum level of low molecular weight BP.

18. Method according to claim 2, wherein the combination is administered to an individual which is insulin-resistant or which has liver disease.